Leslie Ballas interviews Hoda Abdel-Aty about the STAMPEDE2 SABR trial, a Phase III randomized study investigating stereotactic ablative body radiotherapy in newly diagnosed oligometastatic prostate cancer patients starting androgen deprivation therapy.
|
